GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice

Cang Chen, Xiuhua Li, Guo Ge, Jingwei Liu, K. C. Biju, Suzette D. Laing, Yusheng Qian, Cori Ballard, Zhixu He, Eliezer Masliah, Robert A Clark, Jason O'connor, Senlin Li

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Glial cell line-derived neurotrophic factor (GDNF) is the most potent neuroprotective agent tested in cellular and animal models of Parkinson's disease (PD). However, CNS delivery of GDNF is restricted by the blood-brain barrier (BBB). Using total body irradiation as transplant preconditioning, we previously reported that hematopoietic stem cell (HSC) transplantation (HSCT)-based macrophage-mediated gene therapy could deliver GDNF to the brain to prevent degeneration of nigrostriatal dopamine (DA) neurons in an acute murine neurotoxicity model. Here, we validate this therapeutic approach in a chronic progressive PD model - the MitoPark mouse, with head shielding to avoid inducing neuroinflammation and compromising BBB integrity. Bone marrow HSCs were transduced ex vivo with a lentiviral vector expressing macrophage promoter-driven GDNF and transplanted into MitoPark mice exhibiting well developed PD-like impairments. Transgene-expressing macrophages infiltrated the midbrains of MitoPark mice, but not normal littermates, and delivered GDNF locally. Macrophage GDNF delivery markedly improved both motor and non-motor symptoms, and dramatically mitigated the loss of both DA neurons in the substantia nigra and tyrosine hydroxylase-positive axonal terminals in the striatum. Our data support further development of this HSCT-based macrophage-mediated GDNF delivery approach in order to address the unmet need for a disease-modifying therapy for PD.

Original languageEnglish (US)
Article number5460
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Dopaminergic Neurons
Macrophages
Parkinson Disease
Blood-Brain Barrier
Whole-Body Irradiation
Hematopoietic Stem Cell Transplantation
Tyrosine 3-Monooxygenase
Neuroprotective Agents
Substantia Nigra
Mesencephalon
Transgenes
Genetic Therapy
Animal Models
Transplantation
Bone Marrow
Head
Transplants
Brain
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice. / Chen, Cang; Li, Xiuhua; Ge, Guo; Liu, Jingwei; Biju, K. C.; Laing, Suzette D.; Qian, Yusheng; Ballard, Cori; He, Zhixu; Masliah, Eliezer; Clark, Robert A; O'connor, Jason; Li, Senlin.

In: Scientific Reports, Vol. 8, No. 1, 5460, 01.12.2018.

Research output: Contribution to journalArticle

Chen, C, Li, X, Ge, G, Liu, J, Biju, KC, Laing, SD, Qian, Y, Ballard, C, He, Z, Masliah, E, Clark, RA, O'connor, J & Li, S 2018, 'GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice', Scientific Reports, vol. 8, no. 1, 5460. https://doi.org/10.1038/s41598-018-23795-4
Chen, Cang ; Li, Xiuhua ; Ge, Guo ; Liu, Jingwei ; Biju, K. C. ; Laing, Suzette D. ; Qian, Yusheng ; Ballard, Cori ; He, Zhixu ; Masliah, Eliezer ; Clark, Robert A ; O'connor, Jason ; Li, Senlin. / GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{b5b3c193a9b04a0796d58d394129a7f9,
title = "GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice",
abstract = "Glial cell line-derived neurotrophic factor (GDNF) is the most potent neuroprotective agent tested in cellular and animal models of Parkinson's disease (PD). However, CNS delivery of GDNF is restricted by the blood-brain barrier (BBB). Using total body irradiation as transplant preconditioning, we previously reported that hematopoietic stem cell (HSC) transplantation (HSCT)-based macrophage-mediated gene therapy could deliver GDNF to the brain to prevent degeneration of nigrostriatal dopamine (DA) neurons in an acute murine neurotoxicity model. Here, we validate this therapeutic approach in a chronic progressive PD model - the MitoPark mouse, with head shielding to avoid inducing neuroinflammation and compromising BBB integrity. Bone marrow HSCs were transduced ex vivo with a lentiviral vector expressing macrophage promoter-driven GDNF and transplanted into MitoPark mice exhibiting well developed PD-like impairments. Transgene-expressing macrophages infiltrated the midbrains of MitoPark mice, but not normal littermates, and delivered GDNF locally. Macrophage GDNF delivery markedly improved both motor and non-motor symptoms, and dramatically mitigated the loss of both DA neurons in the substantia nigra and tyrosine hydroxylase-positive axonal terminals in the striatum. Our data support further development of this HSCT-based macrophage-mediated GDNF delivery approach in order to address the unmet need for a disease-modifying therapy for PD.",
author = "Cang Chen and Xiuhua Li and Guo Ge and Jingwei Liu and Biju, {K. C.} and Laing, {Suzette D.} and Yusheng Qian and Cori Ballard and Zhixu He and Eliezer Masliah and Clark, {Robert A} and Jason O'connor and Senlin Li",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-23795-4",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice

AU - Chen, Cang

AU - Li, Xiuhua

AU - Ge, Guo

AU - Liu, Jingwei

AU - Biju, K. C.

AU - Laing, Suzette D.

AU - Qian, Yusheng

AU - Ballard, Cori

AU - He, Zhixu

AU - Masliah, Eliezer

AU - Clark, Robert A

AU - O'connor, Jason

AU - Li, Senlin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Glial cell line-derived neurotrophic factor (GDNF) is the most potent neuroprotective agent tested in cellular and animal models of Parkinson's disease (PD). However, CNS delivery of GDNF is restricted by the blood-brain barrier (BBB). Using total body irradiation as transplant preconditioning, we previously reported that hematopoietic stem cell (HSC) transplantation (HSCT)-based macrophage-mediated gene therapy could deliver GDNF to the brain to prevent degeneration of nigrostriatal dopamine (DA) neurons in an acute murine neurotoxicity model. Here, we validate this therapeutic approach in a chronic progressive PD model - the MitoPark mouse, with head shielding to avoid inducing neuroinflammation and compromising BBB integrity. Bone marrow HSCs were transduced ex vivo with a lentiviral vector expressing macrophage promoter-driven GDNF and transplanted into MitoPark mice exhibiting well developed PD-like impairments. Transgene-expressing macrophages infiltrated the midbrains of MitoPark mice, but not normal littermates, and delivered GDNF locally. Macrophage GDNF delivery markedly improved both motor and non-motor symptoms, and dramatically mitigated the loss of both DA neurons in the substantia nigra and tyrosine hydroxylase-positive axonal terminals in the striatum. Our data support further development of this HSCT-based macrophage-mediated GDNF delivery approach in order to address the unmet need for a disease-modifying therapy for PD.

AB - Glial cell line-derived neurotrophic factor (GDNF) is the most potent neuroprotective agent tested in cellular and animal models of Parkinson's disease (PD). However, CNS delivery of GDNF is restricted by the blood-brain barrier (BBB). Using total body irradiation as transplant preconditioning, we previously reported that hematopoietic stem cell (HSC) transplantation (HSCT)-based macrophage-mediated gene therapy could deliver GDNF to the brain to prevent degeneration of nigrostriatal dopamine (DA) neurons in an acute murine neurotoxicity model. Here, we validate this therapeutic approach in a chronic progressive PD model - the MitoPark mouse, with head shielding to avoid inducing neuroinflammation and compromising BBB integrity. Bone marrow HSCs were transduced ex vivo with a lentiviral vector expressing macrophage promoter-driven GDNF and transplanted into MitoPark mice exhibiting well developed PD-like impairments. Transgene-expressing macrophages infiltrated the midbrains of MitoPark mice, but not normal littermates, and delivered GDNF locally. Macrophage GDNF delivery markedly improved both motor and non-motor symptoms, and dramatically mitigated the loss of both DA neurons in the substantia nigra and tyrosine hydroxylase-positive axonal terminals in the striatum. Our data support further development of this HSCT-based macrophage-mediated GDNF delivery approach in order to address the unmet need for a disease-modifying therapy for PD.

UR - http://www.scopus.com/inward/record.url?scp=85044951800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044951800&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-23795-4

DO - 10.1038/s41598-018-23795-4

M3 - Article

C2 - 29615705

AN - SCOPUS:85044951800

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 5460

ER -